Telehealth Law · Telemedicine Defense · DEA Flexibilities · Ryan Haight Act · State Licensure

Telehealth Law & Telemedicine Attorneys

Defense for telehealth and telemedicine providers facing DEA, Ryan Haight Act, and payor audit scrutiny.

Request a Free Case Review
Audit Hotline - Direct Line
(800) 345 - 4125
Speak with an attorney - not a call center. Immediate response.
Telehealth Law & Telemedicine Briefing

Audit Contractors and Defense Scope

Telehealth and telemedicine continue to operate under the post-PHE regulatory framework that combines DEA telemedicine flexibilities, the Ryan Haight Act's in-person evaluation requirements, state-by-state telehealth licensure rules, and payor audit programs that increasingly target telehealth-mediated prescribing patterns.

Health Law Alliance defends telehealth platforms, prescribing physicians, dispensing pharmacies, and ancillary providers across DEA flexibility audits, Ryan Haight Act enforcement, state licensure proceedings, and payor audit defense. The defense framework is one matter across federal, state, and payor layers.

$4.7M
Largest GLP-1 Recoupment Reversed
96%
Of Reviewed Findings Overturned on Appeal
2,000+
Audits Overseen by Our Bench
Immediate
Response - Audit Notices Don't Wait
Former officials from the agencies & PBMs auditing your pharmacy
U.S. Department of Justice
DOJ
FBI
FBI
HHS OIG
HHS-OIG
DEA
DEA
OptumRx
OptumRx
McKesson
McKesson
NAMFCU
NAMFCU
U.S. Treasury
Treasury
Client Reviews
What Clients Say
5.07 Google reviews
Telehealth & Telepharmacy Regulatory Law
What We Do
01
Advise on platform regulatory risk minimization
02
Counsel on legal structuring (setting up Management Services Organizations (MSOs), drafting vendor agreements, billing and sales force categorization.
03
Providing launch checklists, billing and patient steering laws.
04
Comprehensive telehealth strategy and State Board of Pharmacy (as well as DEA) telepharmacy rules.
05
Navigating the Corporate Practice of Medicine (CPOM), fee-splitting prohibitions, and fraud-and-abuse laws like the Anti-Kickback Statute.
06
Multi-state licensing support for nonresident pharmacy licensing
07
Regulatory support for remote prescription processing
08
Review of Website L&A. Handling Federal Trade Commission false and misleading advertising claims.
09
Accreditation such as NABP’s Digital Pharmacy Accreditation Program, formerly known as Verified Internet Pharmacy Practice Sites (VIPPS) and/or LegitScript
10
Guidance for Clinically integrated networks (CINs) involving pharmacies
"By the time the audit letter arrives, you have 30 days. The pharmacies that win are the ones that mobilize in the first 72 hours."
Protect Your Pharmacy Now →
Illustrative stack of legal and medical records prepared for document review
Document review · Illustrative image, not a client record
Document Review

The document response shapes the next procedural stage

The first response is not a routine administrative task. It establishes the documents, timing, and record the contractor can later use in its findings and on appeal.

Notice and deadlineIdentify the review posture and protect the earliest response window.
Contractor and review typeConfirm whether the matter is a document request, prepayment review, postpayment review, or focused medical review.
Scope and requested recordsReview the claim universe and the requested records before producing a file that cannot be taken back.
Health Law Alliance attorneys
The HLA Bench

The HLA Telehealth Law & Telemedicine Team

Health Law Alliance handles the response and any parallel appeal, licensing matter or referral as one coordinated matter, so the strategy does not change hands as the matter moves between forums.

The bench includes a former Assistant U.S. Attorney nominated for the DOJ Director's Award, senior healthcare-company counsel, and attorney-providers with experience across healthcare audits and investigations.

Health Law Alliance

Firm record

5,000+Matters handled
2,500+Clients represented
2,000+Audits overseen
ImmediateAttorney response
Former professional experience

Where Our Attorneys Served Before Health Law Alliance

Department of Justice Former Assistant U.S. Attorney
Drug Enforcement Administration Former DEA Diversion Control Program Manager
OptumRx Former senior executive experience
McKesson Former healthcare-industry experience

Agency and company marks identify former professional experience of individual HLA team members. They do not imply affiliation, endorsement, or a client relationship.

Recent GLP-1 Outcomes
Representative Case Results

Outcomes are summarized for confidentiality. Client names, precise geography, and identifying facts are redacted.

Case files Recoupment Reversed
OptumRx GLP-1 Audit - $4.7M Demand Reduced to $180K.

Multi-location independent pharmacy faced an OptumRx full-scope GLP-1 audit covering 2023 to 2025 semaglutide and tirzepatide claims. HLA reconstructed the PA chain for every flagged fill and documented extrapolation errors; final settlement reflected a 96% reduction.

Southeast · 3 locations · 2026
Pharmacy interior Network Reinstated
Caremark Termination Notice - Full Network Reinstatement.

Single-location pharmacy received a Caremark "termination for cause" tied to compounded semaglutide dispensing during the FDA shortage period. HLA's appeal brief led to full reinstatement across Caremark, SilverScript and Aetna networks without a recoupment.

Northeast · 1 location · 2025
Document closure State Board Closed
State Board of Pharmacy Referral - Investigation Closed, No Action.

Compounding pharmacy was referred to the state board by an Express Scripts auditor alleging off-label tirzepatide dispensing. HLA's regulatory response demonstrated full compliance with USP 797 and FDA guidance in effect at the time; the board closed the matter with no discipline.

Midwest · 1 location · 2025

Attorney advertising. Prior results do not guarantee a similar outcome. Case summaries are generalized for confidentiality and are not a substitute for legal advice on your specific audit.

GLP-1 Audit FAQ
Frequently Asked Questions

Seven questions that come up on almost every first call.

I just received an OptumRx or Caremark GLP-1 audit notice. How long do I have? +
The written response window is typically 30 days from the date on the notice, but document-production deadlines inside the notice are often shorter - sometimes as little as 10 business days. The first 72 hours are the most important: preserve the flagged claims' adjudication logs, identify every prescriber of record, and put a litigation hold in place. Missing the production deadline can waive your ability to appeal on the merits.
How do PBMs pick which pharmacies to audit for GLP-1 claims? +
Analytics first, complaints second. PBM data teams rank pharmacies by GLP-1 share of total revenue, telehealth-clinic prescriber concentration, out-of-state dispensing percentage, and any compounded-semaglutide billing. A pharmacy in the top decile on any two of those metrics has a meaningfully elevated audit probability regardless of actual compliance posture.
My claims had approved prior auths. Can the PBM still recoup? +
Yes - and this is the single most misunderstood part of GLP-1 audits. PBMs are invoking contractual "right to audit" provisions to re-review previously approved PAs against the plan's clinical criteria in force at the time of fill. The defense is to pull the PBM's own adjudication rationale and the plan's published criteria for that dispense date. An approved PA is evidence, not a safe harbor, but it's strong evidence when defended properly.
What about compounded semaglutide or tirzepatide? Is there any defense? +
Yes, and it's fact-specific. Compounding during an FDA-declared shortage operates under 503A / 503B pathways that PBMs routinely mis-apply post hoc. The defense looks at shortage status on the dispense date, the prescriber's documented medical-necessity rationale, USP 797 compliance, and state board posture. Compounded-GLP-1 matters typically need coordinated PBM, DEA / FDA, and state board defense - which is our core practice.
Will engaging counsel make the PBM more aggressive? +
In our experience, the opposite. PBM audit teams close matters faster - and at much lower recoupment figures - when the pharmacy is represented by counsel with a track record of federal litigation. Our attorneys include former OptumRx senior executives; audit teams recognize when a file is being defended on a path to federal court versus processed like a typical pharmacy response, and the settlement posture changes accordingly.
What does HLA cost, and how is the engagement structured? +
We scope each matter individually. A typical GLP-1 audit defense is a flat-fee engagement tied to the phase of work (notice response, appeal, litigation), so you know your exposure upfront. For pharmacies facing potential termination, we offer expedited emergency engagement. Every engagement starts with a free, privileged consultation - no retainer required.
I haven't been audited yet, but I'm worried. Is it too early to call? +
No - it's the right time. Proactive review is dramatically cheaper than reactive defense. We offer a GLP-1 compliance audit where our team reviews a sample of your semaglutide / tirzepatide claims against current PBM criteria, identifies the fills most likely to be flagged, and helps you remediate documentation gaps before a PBM notice arrives. Every pharmacy owner we've put through this has told us it was the single highest-leverage expense of the year.
Speak with an Attorney Today

Get a free, privileged review of your matter before you respond

Before you write a single page of your written response, have a privileged conversation with attorneys who have overseen 2,000+ audits - from both sides of the table. Free, confidential, no retainer.

"HLA turned a $3.2M OptumRx recoupment into a $144K settlement. They knew the OptumRx playbook better than OptumRx did - which, given their partner ran audits at Optum, made perfect sense. We would have sold the pharmacy without them." - Owner, 4-Location Independent Pharmacy (Pilot Client, 2026)
Under a GLP-1 audit? Speak with an attorney today.